INT122481

From wiki-pain
Revision as of 09:06, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 13
Disease Relevance 6.10
Pain Relevance 1.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (PLAU) signal transduction (PLAU) extracellular space (PLAU)
extracellular region (PLAU) plasma membrane (PLAU)
PLAU (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 6 98.76 Very High Very High Very High
Inflammation 16 96.76 Very High Very High Very High
metalloproteinase 106 95.40 Very High Very High Very High
methotrexate 3 85.28 High High
Arthritis 2 81.36 Quite High
Osteoarthritis 66 77.72 Quite High
antagonist 13 75.68 Quite High
Potency 4 74.80 Quite High
cytokine 21 70.52 Quite High
Pain 6 60.72 Quite High
Disease Link Frequency Relevance Heat
Cancer 204 100.00 Very High Very High Very High
Metastasis 132 99.48 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 4 99.10 Very High Very High Very High
Disease 31 98.40 Very High Very High Very High
Aggression 6 98.08 Very High Very High Very High
Injury 1 97.20 Very High Very High Very High
INFLAMMATION 15 96.76 Very High Very High Very High
Hypersensitivity 4 95.88 Very High Very High Very High
Breast Cancer 167 95.80 Very High Very High Very High
Recurrence 30 89.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast, low uPA mRNA expression was not significantly associated with longer metastasis-free survival (p = 0.41) (Figure 4).
uPA Binding (associated) of associated with metastasis
1) Confidence 0.36 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1564186 Disease Relevance 0.37 Pain Relevance 0
Nevertheless, in metastatic breast cancer, retrospective studies showed that elevated uPA or PAI-1 present in the primary tumor are associated with a poor response to later palliative endocrine therapy [14] suggesting that high levels of uPA and/or PAI-1 do reflect an aggressive phenotype that may be overcome by early systemic therapy in the adjuvant setting but not by palliative therapy at a later stage of the disease.
uPA Binding (associated) of associated with cancer, disease, advanced or metastatic breast cancer and palliative
2) Confidence 0.36 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1564186 Disease Relevance 0.81 Pain Relevance 0.23
Several international research groups have demonstrated that the protein content of uPA and PAI-1 in the tumor correlates with disease aggressiveness and has a strong prognostic impact on disease-free survival and overall survival in patients with primary breast cancer [1-6].
uPA Binding (content) of associated with cancer, breast cancer, aggression and disease
3) Confidence 0.35 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1564186 Disease Relevance 0.90 Pain Relevance 0
UPA EC has been shown to be associated with a lower pregnancy rate compared to LNG EC.
UPA EC Binding (associated) of
4) Confidence 0.30 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971744 Disease Relevance 0.29 Pain Relevance 0
Pre-clinical studies indicate that UPA binds to human progesterone, glucocorticoid and androgen receptors at approximately 6, 1.5 and 0.2 times the affinity of the endogenous ligands and shows in vivo anti-glucocorticoid and anti-androgen activity at doses approximately 50-fold greater than those needed for anti-progestin effect.
UPA Binding (binds) of
5) Confidence 0.28 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971744 Disease Relevance 0.06 Pain Relevance 0.08
The databases from the two randomized controlled trials comparing UPA with LNG EC (n = 1549 women treated <72 hours after unprotected intercourse plus 1899 women treated <120 hours) were merged in a meta-analysis including the primary efficacy populations defined in each study.47 Comparisons were done for different time windows of treatment in relation to unprotected intercourse.
UPA Binding (comparing) of
6) Confidence 0.26 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971744 Disease Relevance 0 Pain Relevance 0
It has recently been demonstrated that binding of u-PA to its receptor increases pro-MMP-2,-9 [23] and -13 [16] activation, and that in the absence of cells, plasmin not only fails to activate pro-MMPs, but rapidly degrades them [23].
u-PA Binding (binding) of associated with metalloproteinase
7) Confidence 0.25 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC548674 Disease Relevance 0.40 Pain Relevance 0.18
Since UPA binds the progesterone receptor with high affinity, it may interfere with the action of progestogen-containing drugs.
UPA Binding (binds) of
8) Confidence 0.25 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2971744 Disease Relevance 0.33 Pain Relevance 0
In combination with other ECM proteins found in our analysis, PAI-1 and uPA, the association with DFI and OS became even more significant (p < 0.001).
uPA Binding (association) of
9) Confidence 0.21 Published 2005 Journal Int. J. Cancer Section Abstract Doc Link 15499618 Disease Relevance 0.51 Pain Relevance 0.06
PAI-1 and PAI-2 belong to the serine protease inhibitor super-family and are involved in the regulation and inhibition of binding between uPA and its receptor.
uPA Binding (binding) of
10) Confidence 0.13 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2956083 Disease Relevance 0.38 Pain Relevance 0
Moreover, interaction between uPA and COX-2 was also shown in some cancer cells [35,36] and in corneal injury and inflammation [37].
uPA Binding (interaction) of associated with inflammation, cancer and injury
11) Confidence 0.11 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246240 Disease Relevance 0.88 Pain Relevance 0.51
Domain 1 is the only domain involved in (pro)-u-PA binding, domain 3 also participates in providing the u-PA binding site.
u-PA Binding (binding) of
12) Confidence 0.04 Published 2004 Journal Reprod Biol Endocrinol Section Body Doc Link PMC320496 Disease Relevance 0.63 Pain Relevance 0.04
The receptor (u-PAR/CD87) focuses the enzymatic activity of u-PA and allows activation of plasminogen (PG) at the cell surface, which in turn, is bound to the cell membrane by ?
u-PA Binding (activity) of
13) Confidence 0.03 Published 2004 Journal Reprod Biol Endocrinol Section Body Doc Link PMC320496 Disease Relevance 0.54 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox